The difference between Selpercatinib and Platinib

Selpercatinib and platinib (Pralsetinib) are RET inhibitors approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with RET fusion-positive non-small cell lung cancer. Without direct comparative data, it is difficult to determine whether one agent is superior to another because both agents have demonstrated similar efficacy, central nervous system penetrance, and tolerability.

Selpatinib is a specificRET tyrosine kinase inhibitor, with an excellent response rate slightly higher than60%. Among those who did not receive treatment, the response rate was well over 80%. This is a very effective and well tolerated drug. The median duration of response is about 17 months, so we're getting deep and durable responses with this drug, and compared to some of the multikinase inhibitors we've used previously to treat patients with RET fusions, serpatinib and platinib have similar toxicities, including hypertension, QT changes

The original drug Serpatinib has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. Serpatinib marketed overseas The original drug has a US version and a European version. The price of the US version is about 150,000 yuan per box of 80mg*60 pills. The price of the European version of 80mg*56 pills per box is about 21,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also serpatinibgeneric drugs produced abroad. The specification produced by a Bangladesh pharmaceutical factory is 40mg*30 pills per box and the price is about 4,300 yuan (the price may fluctuate due to the exchange rate). The ingredients of the generic drugs are basically the same as those of the original drug.